secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2024-11-21T23:59:59+00:00
Accession:  0001193125-24-263406
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte amends HQ lease to 258,581 RSF, subleases 16,731 SF to Iovance Biotherapeutics
--------------------------------------------------------------------------------

- Amended lease expands premises from ~113k to 258,581 RSF across floors 1-6, phased move-ins Feb 2025 through June 2026.
- Initial base rent $5.941-$6.026/RSF/month for existing premises; $6.00/RSF for additional; 8-month abatement, 3% annual escalations.
- Lease term 120 months from first additional premises commencement, with two 5-year renewal options.
- Subleased 16,731 RSF of Suite 100A to Iovance Biotherapeutics for 2 years at $5.95/RSF, rising to $6.1285/RSF after year one.
- Security deposit of ~$1.09M in letters of credit carried over from prior leases.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000119312524263406/0001193125-24-263406-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000119312524263406/d847442d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-263406

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer